Neurodiagnostics: Brain Imaging, Biomarkers and NeuroInformatics Analyzed by NeuroInsights
SAN FRANCISCO, February 13-- Neurodiagnostics is the focus of a new report released today by NeuroInsights, the neurotech market authority. The industry insider report on innovative research and development in imaging, in vitro diagnostics and informatics for the brain and nervous system provides unique insights into the key players and competitive dynamics in this rapidly evolving field.
Nearly 2 billion people worldwide and 100 million people in the US are affected by a brain or nervous system disorder including addiction, Alzheimer’s, depression, anxiety, schizophrenia, attention disorders, epilepsy, Parkinson’s disease, sensory disorders, and sleep disorders. Diagnosis of these disorders is rapidly changing as new tools are developed for more objective and personalized assessment and treatment.
In addition to the massive unmet markets, long term growth in neurodiagnostics is being driven by 1) technology advances and equipment upgrades in neuroimaging, 2) new biomarkers and imaging protocols for early diagnosis and disease monitoring, and 3) increased use of imaging and informatics in drug and device development.
The report analyzes the scientific approaches and challenges to developing CNS diagnostics, discusses trends and drivers including funding and regulatory issues, reveals promising products in development, and sheds light on investment opportunities and risks. It provides profiles of over 170 companies that are shaping the field and spearheading diagnostics and monitoring for the brain and nervous system.
The 100 page report, “The Neurodiagnostics Report: An industry insider report on markets and emerging diagnostics in neurology and psychiatry. ” is available immediately for purchase from NeuroInsights at http://www.neuroinsights.com/marketreports/neurodiagnosticsreport.html or can be ordered by calling NeuroInsights at 415-229-3225.
About NeuroInsights
NeuroInsights is the world’s leading neurotechnology research and advisory firm. As the neurotechnology market authority, NeuroInsights helps investors, industry and society understand and profit from the rapid growth in drugs, devices, cell-based therapeutics and diagnostics for the brain and nervous system. NeuroInsights provides market reports, investment information, industry events and strategic advisory services to venture funds, startups, corporations, governments and financial institutions. NeuroInsights created and maintains the NASDAQ(R) NeuroInsights(R) Neurotech Index (NASDAQ: NERV), a pure play modified market-capitalization weighted index designed to track the performance of the leading neurotechnology companies which are listed and actively traded on one of the three major U.S. stock exchanges.
|
|